A pilot study of interferon α-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2399-2408

  Shapiro, Jeremy D ^a   Harold, Nancy ^a   Takimoto, Chris ^a   Hamilton, J Michael ^a   Vaughn, David ^b   Chen, Alice ^a   Steinberg, Seth M ^a   Liewehr, David ^a   Allegra, Carmen ^a   Monahan, Brian ^c   Lash, Alex ^a   Grollman, Frank ^a   Flemming, Donald ^c   Behan, Katherine ^a   Johnston, Patrick G ^a   Haller, Daniel ^b   Quinn, Mary ^a   Morrison, Geraldine ^a   Grem, Jean L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; GASTROINTESTINAL CARCINOMA; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON ALFA-2B; LEUCOVORIN; MALE; MIDDLE AGED; PILOT PROJECTS; QUALITY OF LIFE; THYMIDYLATE SYNTHASE;

EID: 0032883417     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Heidelberger, C., Chaudhuari, N. K., and Danenberg, P. Fluorinated pyrimidines: a new class of tumor inhibitory compounds. Nature (Lond.), 179: 663-666, 1957.
2. Grem, J. L. Fluorinated pyrimidines. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy: Principles and Practice, Ed. 2, pp. 149-212. Philadelphia: J. B. Lippincott, 1996.
3. Cohen, A., Minsky, B., and Schilsky, R. Cancer of the colon. In: V. T. DeVita, Jr., S. Hellman, and S. Rosenberg (eds.), Cancer-Principles and Practice of Oncology, Ed. 5, pp. 1144-1196. Philadelphia: J. B. Lippincott, 1997.
4. Moertel, C. G., and Reitemeyer, R. J. (eds). Advanced gastrointestinal cancer: clinical management and chemotherapy. New York: Harper and Row, 1969.
5. The advanced colorectal cancer meta-analysis project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10: 896-903, 1992.
6. Elias, L., and Crissman, H. A. Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites. Cancer Res., 48: 4861-4873, 1988.
7. Wadler, S., Wersto, R., Weinberg, V., Wiernik, P. H. Interaction of fluorouracil and Interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res., 50: 5735-5739, 1990.
8. Schwartz, E. L., Hoffman, M., O'Connor, C. J., and Wadler, S. Stimulation of 5-fluorouracil metabolic activation by interferon-α in human colon carcinoma cell lines. Biochem. Biophys. Res. Commun., 182: 1232-1239, 1992.
9. Chu, E., Zinn, S., Boarman, D., and Allegra, C. J. Interaction of γ Interferon and fluorouracil in the H630 human colon carcinoma cell line. Cancer Res., 50: 5834-5840, 1990.
10. Le, J., Yip, Y. K., and Vilcek, J. Cytologic activity of interferon-γ and its synergism with 5-fluorouracil. Int. J. Cancer, 34: 495-500, 1984.
11. Houghton, J. A., Morton, C. L., Adkins, D. A., and Rahman, A. Locus of the interaction among 5-fluorouracil, leucovorin, and interferon α-2a in colon carcinoma cells. Cancer Res., 53: 4243-4250, 1993.
12. Wadler, S., Schwartz, E. L., Goldman, M., Lyver, A., Rader, M., Zimmerman, M., Itri, L., Weinberg, V., and Wiernik, P. H. Fluorouracil and recombinant α-2a-interferon: an active regimen against advanced colorectal carcinoma. J. Clin. Oncol., 7: 1769-1775, 1989.
13. Kemeny, N., Younes, A., Seiter, K., Kelsen, D., Sammarco, P., Adams, L., Derby, S., Murray, P., and Houston, C. Interferon α-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity. Cancer (Phila.), 66: 2470-2475, 1990.
14. Pazdur, R., Ajani, J. A., Patt, Y. Z., Winn, R., Jackson, D., Shepard, B., DuBrow, R., Campos, L., Quaraishi, M., and Faintuch, J. Phase II study of fluorouracil and recombinant Interferon α-2a in previously untreated advanced colorectal carcinoma. J. Clin. Oncol., 9: 2027-2031, 1991.
15. Wadler, S., Lembersky, B., Atkins, M., Kirkwood, J., and Petrelli, N. Phase II trial of fluorouracil and recombinant interferon α-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J. Clin. Oncol., 9: 1806-1810, 1991.
16. Grem, J. L., Chu, E., Boarman, D., Balis, F. M., Murphy, R. F., McAtee, N., and Allegra, C. J. Biochemical modulation of 5-fluorouracil with leucovorin and interferon: preclinical and clinical investigations. Semin. Oncol., 19 (Suppl. 2): 36-44, 1992.
17. Grem, J. L., McAtee, N., Murphy, R., Steinberg, S., Balis, F. M., Steinberg, S. M., Hamilton, J. M., Sorensen, J. M., Sartor, O., Kramer, B. S., Goldstein, L. J., Gay, L. M., Caubo, K. M., Goldspiel, B., and Allegra, C. A pilot study of interferon α-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. J. Clin. Oncol., 9: 1811-1820, 1991.
18. Grem, J. L., Jordan, E., Robson, M. E., Binder, R. A., Hamilton, J. M., Steinberg, S. M., Arbuck, S. G., Beveridge, R. A., Kales, A., Miller, J. A., Weiss, R. B., NcAtee, N., Chen, A., Goldspiel, B., Sover, E., and Allegra, C. J. Phase II study of fluorouracil, leucovorin, and interferon α-2a in metastatic colorectal carcinoma. J. Clin. Oncol., 9: 1737-1745, 1993.
19. Lieschke, G. J., and Burgess, A. W. Granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor. N. Engl. J. Med., 327: 28-35, 99-106, 1992.
20. Gabrilove, J. L., Jakubowski, A., Scher, H., Sternberg, C., Wong, G., Grous, J., Yagoda, A., Fain, K., Moore, M. A., and Clarkson, B. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N. Engl. J. Med., 318: 1414-1422, 1988.
21. Grem, J. L., McAtee, N., Murphy, R. F., Hamilton, J. M., Balis, F., Steinberg, S., Arbuck, S. G., Setser, A., Jordan, E., Chen, A., Kohler, D. R., Kotite, B., and Allegra, C. J. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. J. Clin. Oncol., 12: 560-568, 1994.
22. Cella, D. F. F. A. C. T. Manual. Manual for the Functional Assessment of Cancer Therapy (FACT) scales and the functional assessment of HIV infection (FAHI) scale. Chicago: Rush-Presbyterian-St. Luke's Medical Center, 1994.
23. Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S. B., Winicour, P., and Brannon, J. The functional assessment of cancer therapy scale: development and validation of the general measure. J. Clin. Oncol., 11: 57057-57059, 1993.
24. Johnston, P. G., Liang, C. M., Henry, S., Chabner, B. A., and Allegra, C. J. Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissues. Cancer Res., 51: 6668-6676, 1991.
25. Hsu, S. M., Raine, L., and Fanger, H. A comparative study of the peroxidase-antiperoxidase method and an avidin biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am. J. Clin. Pathol., 75: 734-738, 1981.
26. Lehmann, E. Nonparametrics. Statistical Methods Based on Ranks, pp. 306-309. San Francisco: Holden-Day, 1975.
27. Breslow, N., and Day, N. E. Statistical Methods in Cancer Research. 1. The Analysis of Case-Control Studies. Lyon: International Agency for Research on Cancer, 1980.
28. Kaplan, E., and Meier, P. Non-parametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
29. Mantel, N. Evaluation of survival data and two new rank order statistics arising on its consideration. Cancer Chemother. Rep., 50: 163-170, 1966.
30. Wadler, S., Atkins, M., Karp, D., Neuberg, D., Haynes, H., and Dutcher, J. P. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon α-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991. Cancer J. Sci. Am., 4: 261-268, 1998.
31. Elias, L., and Sandoval, J. M. Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem. Biophys. Res. Commun., 182: 1232-1239, 1992.
32. Hill, M., Norman, A., Cunningham, D., Findlay, M., Nicolson, V., Hill, A., Iveson, A., Evans, C., Joffe, J., Nicolson, M., and Hickish, N. Royal Marsden Phase III trial of fluorouracil with or without interferon α-2b in advanced colorectal cancer. J. Clin. Oncol., 13: 1297-1302, 1995.
33. Hill, M., Norman, A., Cunningham, D., Findlay, M., Watson, M., Nicolson, V., Webb, A., Middleton, G., Ahmed, F., Hickish, T., Nicolson, M., O'Brien, M., Iveson, T., Iveson, A., and Evans, C. Impact of protracted venous infusion 5-fluorouracil with or without interferon α-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J. Clin. Oncol., 13: 2317-2323, 1995.
34. Corfu-A Study Group. Phase III randomized study of two fluorouracil combinations with either interferon α-2a or leucovorin for advanced colorectal cancer. J. Clin. Oncol., 13: 921-928, 1995.
35. Kohne, C. H., Wilke, H., Hecker, H. Schoffski, P., Kaufer, C., Rauschecker, H., Andreesen, R., Ohl, U., Lange, H. J., and Klaassen, U. Interferon-α does not improve the antineoplastic activity of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. Ann. Oncol., 6: 461-466, 1995.
36. Seymour, M. T., Slevin, M. L., Kerr, M. L., Cunningham, D., James, R. D., Ledermann, J. A., Perren, T. J., McAdam, W. A., Harper, P. G., Neoptolemos, J. P., Nicolson, M., Duffy, A. M., Stephens, R. J., Stenning, S. P., and Taylor, I. Randomized trial assessing the addition of interferon α-2a to fluorouracil and leucovorin in advanced colorectal cancer. J. Clin. Oncol., 14: 2280-2288, 1996.
37. Recchia, F., Nuzzo, A., Lalli, A., Lombardo, M., Di Lullo, L., Fabiani, F., Fanini, R., Venturoni, L., Torchio, P., and Peretti, G. Randomized trial of 5-fluorouracil and high-dose folinic acid with or without α-2b interferon in advanced colorectal cancer. Am. J. Clin. Oncol., 19: 301-304, 1996.
38. Wolmark, N., Bryant, J., Smith, R., Grem, J., Allegra, C., Hyams, D., Atkins, J., Dimitrov, N., Oishi, R., Prager, D., Fehrenbacher, L., Romond, E., Colangelo, L., and Fisher, B., Adjuvant 5-fluorouracil, and leucovorin with or without interferon α-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol C-05. J. Natl. Cancer Inst., 90: 1810-1816, 1998.
39. Peters, G. J., Van der Wilt, C. L., Van Groeningen, C. J., Smid, K., Meijer, S., and Pinedo, H. M. Thymidylate synthase inhibition after administration of fluorouracil with and without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J. Clin. Oncol., 12: 2035-2042, 1994.
40. Lenz, H. J., Leichman, C. G., Danenberg, K. D., Danenberg P. V., Groshen, S., Cohen, H., Laine, L., Crookes, P., Silberman, H., Baranda, J., Garcia, Y., Li, J., and Leichman, L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J. Clin. Oncol., 14: 176-182, 1996.
41. Leichman, C. G., Lenz, H. J., Leichman, L., Danenberg, K., Baranda, J., Groshen, S., Boswell, W., Metzger, R., Tan, M., and Danenberg, P. V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol., 15: 3223-3229, 1997.
42. Findlay, M. P. N., Cunningham, D., Morgan, G., Clinton, S., Hardcastle, A., and Aherne, G. W. Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br. J. Cancer, 75: 903-909, 1997.
43. Benson, A. B., III, Catalano, P. J., Rao, S., Haller, D. G., O'Dwyer, P. J., Allegra, C. J., and Johnston, P. G. Thymidylate synthase expression as a predictor for response to 5-fluorouracil based therapy and survival for patients with resected colon or advanced colorectal cancer. An ECOG study. Proc. Am. Soc. Clin. Oncol., 16: 917, 1997.
44. Alexander, H. R., Grem, J. L., Hamilton, J. M., Pass, H. I., Hong, M., Fraker, D. L., Steinberg, S. M., McAtee, N., Allegra, C. J., and Johnston, P. G. Thymidylate synthase protein expression. Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma. Cancer J. Sci. Am., 1: 49-54, 1995.
45. Johnston, P. G., Fisher, E. R., Rockette, H. E., Fisher, B., Wolmark, N., Drake, J. C., Chabner, B. A., and Allegra, C. J. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol., 12: 2640-2647, 1994.